Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Boulder, Colorado that makes swallowed pills designed to treat serious muscle diseases. Its drugs tune myosin, the protein that drives muscle contraction, to protect fragile fibers in muscular dystrophies and to ease the stiff, thickened heart muscle of hypertrophic cardiomyopathy. Founded in 2017 by four scientists and drug developers, the company went public on Nasdaq in 2021.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.01 Completion of Acquisition or Disposition of Assets · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits